10x Genomics (TXG): Can It Reach $100 for a +56% Gain?
Key Takeaways
- The selected target: $100 per share, a round-number psychological milestone roughly 56% above recent trading levels.
- Strongest bullish factor: Accelerating adoption of the Atera platform, a 74% gross margin, and raised 2026 revenue guidance of $610–$630 million.
- Biggest obstacle: The stock already trades above the average analyst price target of about $49–$50, and the company remains unprofitable on a GAAP basis.
- Key levels: The 52-week high near $64.50 now acts as near-term resistance, while prior breakout zones in the upper $40s to low $50s serve as potential support.
- Bottom line: Reaching $100 is possible over a longer horizon, but it would require sustained revenue re-acceleration and a significant re-rating beyond current analyst expectations.
Why the $100 Level Stands Out
The $100 stock price target carries special weight because it is a clean psychological threshold rather than a technical measurement. For a company whose shares traded below $12 within the past year, crossing into triple digits would symbolize a full-scale turnaround and cement its place among high-multiple life science growth names. It is also a level that naturally captures retail and institutional attention, making it a frequent subject of search-driven market discussion.
Company Overview
10x Genomics is a life science technology company that develops instruments, consumables, and software used to study biology at single-cell and spatial resolution. Its flagship platforms include the Chromium single-cell system and the Xenium spatial biology instrument, with the newer Atera platform increasingly central to the growth narrative. The company went public in 2019 and carries a market capitalization of roughly $8.3 billion.
Current Market Position
TXG recently traded around $63–$64, near the top of its 52-week range of $11.16 to $64.53. The move reflects a sharp re-rating driven by improving fundamentals rather than broad market drift. The stock's five-year beta of roughly 2.0 underscores its volatility: it can gain or lose ground far faster than the broader market, which cuts both ways when evaluating a target as ambitious as $100.
What Could Drive the Next Leg Higher
Several verified fundamentals support continued upside. In its most recent quarter, the company reported revenue of about $151 million, ahead of expectations, with a non-GAAP loss narrower than forecast. Management raised full-year 2026 revenue guidance to a range of $610–$630 million, citing strong early demand for the Atera platform. Gross margin improved to roughly 74%, signaling that core products are high-margin and scaling efficiently even before the business reaches sustained profitability.
Strategic collaborations — including work with major cancer research institutions on single-cell and spatial tumor profiling — also reinforce the long-term thesis that genomics tools are becoming integral to precision medicine and drug discovery. If these partnerships translate into broader consumable pull-through, revenue growth could re-accelerate and support a higher valuation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Prevent the Move
The primary obstacle is valuation and profitability. The company still reports negative earnings per share, and its price-to-sales multiple sits well into double digits. More notably, the consensus analyst price target stands near $49.50 — below the current share price — with even the most bullish published target at $65. In other words, Wall Street's base-case expectation is that the stock has already priced in much of the near-term good news.
Reaching $100 would require the market to re-rate the stock to a multiple roughly 50% above even the highest current analyst target. That would likely demand not just revenue growth but a credible, visible path to profitability, sustained gross-margin gains, and continued success with Atera against well-funded competitors in the single-cell and spatial biology space.
Analyst Opinions and Price Targets
Following the recent earnings report, several firms raised their targets: Stifel lifted its target to $50, while Canaccord Genuity moved to $60 and Stephens raised its target to $65. Others, including Morgan Stanley, J.P. Morgan, and Citi, remain more cautious with neutral ratings and targets in the $40–$50 range. The dispersion — from roughly $40 to $65 — reflects genuine disagreement about whether the recent momentum can persist. Notably, none of these targets approach $100, meaning the selected objective sits far outside the current analyst consensus and would require a fundamentally different earnings trajectory.
Technical Levels That Matter
From a technical analysis standpoint, the prior 52-week high near $64.50 is the immediate resistance level that must first be cleared and held. A sustained breakout above that zone would remove the last remaining overhang from the stock's recent peak. On the downside, the upper $40s to low $50s — where the stock consolidated before its latest leg higher — represent a meaningful support zone that could act as a floor if momentum fades. The $100 level itself would be the next major psychological resistance, but it is not anchored by prior price history, making it more of an aspirational target than a defined supply zone.
Final Assessment
On balance, a move to $100 appears plausible only over a longer time horizon and would require conditions that are not yet in place. The strongest supports are real: accelerating Atera adoption, a high gross margin, and upwardly revised revenue guidance give the growth story tangible momentum. The largest headwinds are equally real: the company remains unprofitable, and its shares already trade above the average analyst price target, with even the most bullish published target at $65. Investors should monitor Atera-related revenue growth, gross-margin trends, the path toward profitability, and whether the stock can decisively hold above its 52-week high. Until the market re-rates the business well beyond current analyst expectations, $100 remains an ambitious — not imminent — objective.
How I Monitor TXG with Tickeron Tools
For traders monitoring whether TXG can sustain its momentum toward higher price targets, I rely on Tickeron’s AI Daily Buy/Sell Signals. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. It helps me surface new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening alone allows.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TXG's RSI Oscillator stays in overbought zone for 5 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TXG broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on TXG as a result. In 72 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for TXG just turned positive on September 14, 2026. Looking at past instances where TXG's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +8.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 191 of 236 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.092) is normal, around the industry mean (10.643). P/E Ratio (0.000) is within average values for comparable stocks, (100.549). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.062). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (39.536).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement